RNA viruses as virotherapy agents - PubMed (original) (raw)

Review

RNA viruses as virotherapy agents

Stephen J Russell. Cancer Gene Ther. 2002 Dec.

Abstract

RNA viruses are rapidly emerging as extraordinarily promising agents for oncolytic virotherapy. Integral to the lifecycles of all RNA viruses is the formation of double-stranded RNA, which activates a spectrum of cellular defense mechanisms including the activation of PKR and the release of interferon. Tumors are frequently defective in their PKR signaling and interferon response pathways, and therefore provide a relatively permissive substrate for the propagation of RNA viruses. For most of the oncolytic RNA viruses currently under study, tumor specificity is either a natural characteristic of the virus, or a serendipitous consequence of adapting the virus to propagate in human tumor cell lines. Further refinement and optimization of these oncolytic agents can be achieved through virus engineering. This article provides a summary of the current status of oncolytic virotherapy efforts for seven different RNA viruses, namely, mumps, Newcastle disease virus, measles virus, vesicular stomatitis virus, influenza, reovirus, and poliovirus.

PubMed Disclaimer

Cited by

The Host Cell Receptors for Measles Virus and Their Interaction with the Viral Hemagglutinin (H) Protein.
Lin LT, Richardson CD. Lin LT, et al. Viruses. 2016 Sep 20;8(9):250. doi: 10.3390/v8090250. Viruses. 2016. PMID: 27657109 Free PMC article. Review.
Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors.
Shime H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Iwakura Y, Tahara H, Inoue N, Seya T. Shime H, et al. Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2066-71. doi: 10.1073/pnas.1113099109. Epub 2012 Jan 19. Proc Natl Acad Sci U S A. 2012. PMID: 22308357 Free PMC article.
Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling.
Rommelfanger DM, Offord CP, Dev J, Bajzer Z, Vile RG, Dingli D. Rommelfanger DM, et al. Gene Ther. 2012 May;19(5):543-9. doi: 10.1038/gt.2011.132. Epub 2011 Sep 15. Gene Ther. 2012. PMID: 21918546 Free PMC article.
Adenoviral virotherapy for malignant brain tumors.
Nandi S, Lesniak MS. Nandi S, et al. Expert Opin Biol Ther. 2009 Jun;9(6):737-47. doi: 10.1517/14712590902988451. Expert Opin Biol Ther. 2009. PMID: 19456208 Free PMC article. Review.
Development of a New Hyaluronic Acid Based Redox-Responsive Nanohydrogel for the Encapsulation of Oncolytic Viruses for Cancer Immunotherapy.
Deng S, Iscaro A, Zambito G, Mijiti Y, Minicucci M, Essand M, Lowik C, Muthana M, Censi R, Mezzanotte L, Di Martino P. Deng S, et al. Nanomaterials (Basel). 2021 Jan 8;11(1):144. doi: 10.3390/nano11010144. Nanomaterials (Basel). 2021. PMID: 33435600 Free PMC article.

RNA viruses as virotherapy agents - PubMed (original) (raw)